Abstract

L-asparaginase, a potential anti-leukemic drug, is used in clinics for the treatment of childhood acute lymphoblastic leukaemia, and is obtained from bacterial origin (Escherichia coli and Erwinia carotovora). The efficacy of L-asparaginase has remained under discussion for bearing many limitations, such as, early clearance from blood plasma and therefore requires multiple administration and various side effects causing immunogenic complications. The present article reviews studies that focused on seeking substitute in L-asparaginase by altering source, such as bacteria, fungi, actinomycetes, algae and plants, as well as reviews strategies like chemical modifications, protein engineering to overcome limitations in drug’s efficacy.

Key words: L-asparaginase, acute lymphoblastic, leukemia, Escherichia coli.